AGCT1532, A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
Study ID: STU-2018-0042
Summary
This trial is an open label, randomized, stratified 2-arm australian-led multicenter phase 3 clinical trial undertaken in two stages. Participants will be randomized via a central system administered by the australian nHMRC Clinical Trials Centre into either a [Quote]standard BeP[Quote] group or [Quote]accelerated BeP[Quote] group. Participants will be assigned to the two treatment arms in a 1:1 ratio and evaluated weekly, and then for 5 years after completing the study to assess the long-term effects of the chemotherapy.
To determine if accelerated BeP (Bleomycin, etoposide, cisPlatin) is superior to standard BeP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs
